Supplemental Table for:
Hepatitis B Surface Antigen Positivity is An Independent Unfavorable Prognostic Factor in Diffuse Large B-cell Lymphoma in The Rituximab Era
Chieh-Lung Cheng et al.

Table S1. Treatment response

Variables†	HBsAg-positive patients (n = 98)	HBsAg-negative patients (n = 318)	P value
Overall response	75 (76.5)	272 (85.5)	0.043
Complete remission	71 (72.4)	259 (81.4)	0.064
Partial remission	4 (4.1)	13 (4.1)	> 0.999
Stable disease	2 (2)	0 (0)	0.055
Progressive disease	16 (16.3)	32 (10.1)	0.104
Induction death	3 (3.1)	12 (3.8)	> 0.999
Not evaluated	2 (2)	2 (0.6)	0.237

† number of patients (%)

Table S2. Binary logistic regression analysis of clinical factors associated with overall response rate in patients with DLBCL

Predictors	Univariate analysis			Multivariate analysis*		
	OR	95% CI	*P* value	OR	95% CI	*P* value
Age < 60 years	2.18	1.277–3.721	0.004	2.107	1.193–3.721	0.01
Female sex	1.383	0.813–2.351	0.232			
ECOG (< 2)	1.846	0.749–4.552	0.183			
Ann Arbor stage (stage I/II)	2.74	1.552–4.838	0.001	2.033	1.119–3.692	0.02
Extranodal sites (< 2)	2.002	1.145–3.5	0.015			
No BM involvement	1.378	0.687–2.762	0.367			
No bulky lesion	1.791	0.831–3.859	0.137			
No B symptoms	1.975	1.17–3.334	0.011			
Normal LDH levels	2.337	1.358–4.024	0.002			
Albumin (≥ 3.5 g/dL)	3.766	2.121–6.69	<0.001	2.926	1.607–5.327	<0.001
No hepatic impairment	2.002	1.085–3.694	0.026			
ALC (> 1000/uL)	1.866	1.076–3.235	0.026			
AMC (< 630/uL)	1.724	0.985–3.02	0.057			
No HBsAg	1.813	1.034 –3.181	0.038	1.895	1.033–3.478	0.039

*Variables significantly associated with overall response rate in univariate analysis were selected for multivariate analysis using backward elimination method (Wald test).
Abbreviations: DLBCL, diffuse large B-cell lymphoma; OR, odds ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; BM, bone marrow; LDH, lactate dehydrogenase; ALC, absolute lymphocyte count; AMC, absolute monocyte count; HBsAg, hepatitis B surface antigen.

Table S3. Multivariate analysis of overall survival and progression-free survival in HBsAg-negative DLBCL patients with data of HBcAb (n = 229)

Variables	Overall survival			Progression-free survival		
	HR	95% CI	*P* value	HR	95% CI	*P* value
NCCN-IPI*	3.066	1.735–5.417	< 0.001	1.834	1.176–2.859	0.007
Albumin†	1.374	0.761–2.48	0.292	1.779	1.093–2.893	0.02
HBcAb$^\Delta$	1.493	0.792 –2.816	0.216	1.693	1.01–2.839	0.046

* High-intermediate/ high versus low/ low-intermediate
† Less than 3.5 g/dL versus more than or equal 3.5 g/dL
$^\Delta$ HBcAb positivity versus HBcAb negativity
Abbreviations: HBsAg, hepatitis B surface antigen; DLBCL, diffuse large B-cell lymphoma; HBcAb, hepatitis B core antibody; HR, hazard ratio; CI, confidence interval; NCCN-IPI, National Comprehensive Cancer Network-International Prognostic Index.